Related Experiment Video

Updated: May 28, 2026

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

Neuropsychological methods in mild cognitive impairment

Valérie Hahn-Barma, Céline Chamayou, Christina Rogan

    Dialogues in Clinical Neuroscience
    |October 29, 2011
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease06:23

    The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

    Published on: October 13, 2016

    Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing06:58

    Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing

    Published on: January 24, 2020

    Related Concept Videos

    Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

    Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

    Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
    Alzheimer's Disease: Overview01:26

    Alzheimer's Disease: Overview

    Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
    The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...